Article Author:
Agam Bansal
Yasar Sattar

Article Editor:
Radia Jamil

Editors In Chief:
James Beauchamp
Mark Pellegrini
Nicole Hale-Crutch

Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes

6/24/2019 9:30:02 AM


Eptifibatide is an antiplatelet drug which reversibly binds and inhibits glycoprotein IIb/IIIa receptor of platelets. A protein found in the venom of a southeastern pygmy rattlesnake is used to make eptifibatide. The PURSUIT and IMPACT-II account for the indications of eptifibatide by Food and Drug Administration(FDA)as mentioned below:

  • Acute coronary syndrome: FDA approved eptifibatide for the medical management of unstable angina (UA) and non-ST elevation myocardial infarction (NSTEMI). In the PURSUIT trial, the eptifibatide showed favorable outcomes in reducing the composite end-point mortality and prevented nonfatal myocardial infarction in patients with non-ST elevation myocardial infarction and unstable angina.[1]
  • Percutaneous coronary intervention (PCI): FDA also approved eptifibatide for patients undergoing PCI including intracoronary stenting. The IMPACT-II trial proved that eptifibatide use with heparin and aspirin reduces ischemic events following a percutaneous coronary intervention (PCI), especially in individuals with unstable angina.[2]

Non-FDA-labeled indications are:

  • Eptifibatide used to enhance myocardial perfusion in the ST-elevation myocardial infarction(STEMI) before PCI as supported by evidence by the "Time to Integrefilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.[3]
  • Another possible use of eptifibatide is to enhance incidence and speed of reperfusion when used in large doses in combination with heparin, aspirin, tissue plasminogen activators in STEMI patients as evidenced by the small group the IMPACT-AMI trial. In the IMPACT-AMI trial, the use of eptifibatide showed complete reperfusion and an early ST-segment recovery on the electrocardiogram.[4]
  • Eptifibatide can be possibly used in combination of TPA in acute ischemic strokes to prevent progression to subacute intracerebral hemorrhage as supported by the "Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR)" trial.[5]

Mechanism of Action

Rupture of atherosclerotic plaque or injury to vessel wall exposes the subendothelial matrix of the coronary blood vessel to circulating platelets. This event triggers a platelet signaling cascade that leads to the activation of the glycoprotein IIb/IIIa receptor (GpIIb/IIIa). The activation of Gp IIb/IIIa receptors leads to cross-linking of fibrinogen to attach multiple platelets to form a durable secondary platelet plug. The secondary platelet plug is essential for progression and stability of the clot. The glycoprotein IIb/IIIa receptor inhibitors including abciximab, eptifibatide, sibrafiban, and tirofiban, which block the activation of Gp IIb/IIIa receptors ultimately preventing clot formation/progression.[6] 

GP IIb/IIIa heterodimer contains a large extracellular region, a transmembrane domain, and a short intracellular cytoplasmic tail. The Gp IIb/IIIa receptor is a calcium and manganese-dependent heterodimer protein consisting of an alpha- and a beta-subunit. The alpha-subunit characterized by three or four divalent Ca or Mn binding domains that are crucial in the GP IIb/IIIa heterodimer. The beta-subunit comprises of disulfide bonds, binding sites including lysine-glycine-aspartic acid (KGD) bindings binding sites or arginine-glycine-aspartic acid (RGD) for attachment of fibrinogen, von Willebrand factor (vWF) and prothrombin. The binding sites of GP IIb/IIIa are hidden as latent and become active on the surface by undergoing a conformational change via inside-out signaling.[7]

The eptifibatide is a natural disintegrin from snake venom and have highly specific binding to the Gp IIb/IIIa receptor because of the structural resemblance of KGD (Lys-Gly-Asp) sequence. Eptifibatide binds to the KGD binding sites on Gp IIb/IIIa receptor and competitively fights against the binding of the receptor with fibrinogen, von Willebrand factor (vWF) and prothrombin. Higher plasma levels of eptifibatide are needed to competitively inhibit the target of over 80% block of KGD binding sites. Eptifibatide can competitively inhibit the KGD (Lys-Gly-Asp) sequence binding site in both active and inactive states. Eptifibatide has a half-life of 2 to 2.5 hrs and cleared by the kidney. The low affinity for direct binding with GP IIb/IIIa is responsible for rapid states. Furthermore, high doses of eptifibatide provide additional antithrombotic benefits by blocking vitronectin binding site, the ligand for alpha-beta in vascular cells, which may offer other antithrombotic benefits.[8][9][10][11]


Eptifibatide is intravenously administered and is available in strengths of 0.75 mg/ml and 2 mg/ml. The dose of eptifibatide is different in patients diagnosed with acute coronary syndrome (ACS) and in patients undergoing percutaneous coronary intervention (PCI). In patients with ACS, it is given immediately after the diagnosis at a loading dose of 180 mcg/kg IV followed by a continuous i.v. infusion of 2 mcg/kg/min. The infusion is continued up to 72 hours. Pre-PCI, eptifibatide is used as a loading dose of 180 mcg/kg IV followed by a continuous infusion of 2 mcg/kg/min with another 180 mcg/kg IV bolus (double bolus regimen) given 10 minutes after the first one. Status post-PCI eptifibatide infusion continued up to 18 hours.  Kidney clears eptifibatide; a maintenance dose is cut down to 50% in patients with serum creatinine greater than 2 mg/dL and keeping loading dose same as that of a normal kidney function. Contraindications to eptifibatide in patients with serum creatinine greater than 4 mg/dL or patients requiring hemodialysis.[12] 

In ACS, eptifibatide is used along with other medications including alteplase, heparin, metoprolol, nitroglycerin, morphine or furosemide. Eptifibatide is chemically incompatible with furosemide, and thus they should not be administered in the same intravenous line.[13][14]

Adverse Effects

The significant side effect of eptifibatide described in the PURSUIT trial was bleeding. In most cases, bleeding was mild and occurred at femoral access sites. There were more red cell transfusions required in the Eptifibatide group compared to placebo to counteract anemia.[1] However, there is increased bleeding following abciximab administration compared to eptifibatide or tirofiban because of rapid reversibility of latter agents.

Thrombocytopenia is another side effect of eptifibatide reported in several case reports.[15][16] Thrombocytopenia infrequently occurs with Gp IIb/IIIa inhibitors but sometimes may be profound. The risk of thrombocytopenia associated with eptifibatide (0.1 to 0.2%) and tirofiban (0.1-0.3%) is lesser compared to abciximab (0.4-1.1%). Tirofiban induced thrombocytopenia (secondary to eptifibatide) occurs because of the naturally occurring drug-dependent antibodies specific for eptifibatide occupied Gp IIb/IIIa receptor site. It is also clinically relevant to distinguish eptifibatide-induced thrombocytopenia from other etiologies. Pseudothrombocytopenia can be seen using complete blood cell analysis when blood samples are collected in EDTA- containing tubes. The absence of platelet clumping on peripheral smear rules out pseudo-thrombocytopenia. Amongst the Gp IIb/IIIa inhibitors, only abciximab has been reported to have an association with pseudo-thrombocytopenia.[17] Heparin and eptifibatide are administered simultaneously during PCI and in treatment of ACS. In comparison to heparin-induced thrombocytopenia (HIT), eptifibatide usually causes a steep decline in platelet count (less than 30000 cells/ uL). HIT-1 occurs within 1 and 5 days whereas HIT-2 occurs within 4 to 20 days following heparin administration.[18] Thus thrombocytopenia developing within the first day or severe thrombocytopenia favor thrombocytopenia secondary to eptifibatide. Also, the detection of platelet factor-4 (PF-4) assay in HIT can help differentiate it from eptifibatide-induced thrombocytopenia. Eptifibatide can inhibit to new platelets in both active and inactive state. Thrombocytopenia due to eptifibatide responds better after discontinuation of medication, and addition of platelet bag is not helpful if the patient has a high concentration of eptifibatide in plasma. Other side effects reported include hypotension, heart failure, arrhythmias (ventricular fibrillation, atrial fibrillation), hypersensitivity reactions, gastrointestinal, genitourinary or pulmonary alveolar hemorrhage.[15]


The contraindications to using eptifibatide mentioned below[19]:

  • Thrombocytopenia: eptifibatide is contraindicated in patients with a platelet count of less than 100000/ ul
  • Renal failure: eptifibatide is contraindicated in patients with serum creatinine higher than 4 mg/dL or patients requiring hemodialysis because of its renal elimination. In such patients, abciximab is an alternative
  • Hypersensitivity to eptifibatide
  • Severe, uncontrolled hypertension
  • History of bleeding diathesis within 30 days
  • Major surgery or trauma within the prior 6 weeks
  • Active internal bleeding or recent significant gastrointestinal or genitourinary bleed within the past 6 months
  • History of stroke within 30 days or hemorrhagic stroke at any time
  • Intracranial neoplasm, arteriovenous malformations, aneurysms or aortic dissection
  • Use of another parenteral glycoprotein IIb/IIIa inhibitor

Eptifibatide is a pregnancy category B drug. It should only be used cautiously in lactating mothers. Also, the drug is not recommended for use in the pediatric population.


Monitor complete blood count (CBC), serum creatinine, and PT/aPTT. In patients undergoing PCI, measure activated clotting time (ACT).[19]

  • CBC: look for thrombocytopenia and anemia due to bleeding. It is strongly recommended to measure platelet count within 2 to 6 hours of administering eptifibatide to detect thrombocytopenia if any.
  • Serum creatinine: Since eptifibatide gets cleared renally, it is essential to monitor renal function tests.
  • PT/aPTT: to monitor the risk of bleeding
  • ACT: eptifibatide is known to have an additive effect on activated clotting time (ACT) when used together with heparin. Therefore, aPTT and ACT should be monitored closely when administering these agents together.


Bleeding at intravenous sites is the most common adverse effect. Simultaneous use of NSAIDs or other antiplatelet drugs and renal insufficiency would increase the risk of bleeding.

There is no specific antidote for eptifibatide toxicity. Eptifibatide should be discontinued when platelet counts are under 50,000 cells/microliter, and a platelet transfusion ordered when platelet counts are less than 20000 cells/microliter, or there is significant bleeding.[15]

Enhancing Healthcare Team Outcomes

Eptifibatide is useful in the treatment of acute coronary syndrome (ACS) and following percutaneous coronary intervention (PCI). Healthcare workers including nurses, pharmacists, and clinicians should be aware that bleeding and thrombocytopenia are major complications following eptifibatide administration and they should work together as a team to identify these complications early to help bring about optimal patient benefit. [Level V] Also, since heparin is used in conjunction with eptifibatide in the treatment of ACS and during PCI, it is imperative to learn how to differentiate heparin-induced thrombocytopenia from eptifibatide-induced thrombocytopenia.

Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Eptifibatide - Questions

Take a quiz of the questions on this article.

Take Quiz
A 57-year old male presents to the emergency department with a 2-hour history of substernal chest pain and diaphoresis. His past medical history is significant for diabetes mellitus diagnosed 20 years ago and is on metformin. He also has a 20 pack-year smoking history. He was diagnosed with chronic kidney disease 5 years ago. His baseline serum creatinine is 2.5 mg/dl. In the emergency department, his ECG shows ST-segment depression. Cardiac markers return positive. His physical examination reveals bilateral pedal edema. His blood pressure is 147/79 mm Hg, pulse is 82/min, and oxygen saturation is 98% on room air. In the emergency department, he is given sublingual nitroglycerin, aspirin, clopidogrel, metoprolol. The treating physician discusses with the patient and family members and plans for percutaneous coronary intervention. Eptifibatide is planned to be given following percutanous coronary intervention. What is the correct method and dose of administration?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up
A 56-year-old male comes to the emergency department with a 2-hour history of chest pain. He was watching television when he had substernal chest pain followed by profuse diaphoresis. He has a 20 pack-year smoking history. His mother had a history of a heart attack. His blood pressure is 138/82 mmHg, pulse is 82/min, and oxygen saturation is 97% on room air. ECG is performed, and it shows ST segment depression. Cardiac enzymes return negative. The patient is started on medications for his condition. Which of the following describes the mechanism of action of eptifibatide in the above described condition?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up

Eptifibatide - References


Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet (London, England). 1997 May 17;     [PubMed]
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The New England journal of medicine. 1998 Aug 13;     [PubMed]
Lefkovits J,Plow EF,Topol EJ, Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. The New England journal of medicine. 1995 Jun 8;     [PubMed]
Sane DC,Damaraju LV,Topol EJ,Cabot CF,Mascelli MA,Harrington RA,Simoons ML,Califf RM, Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. Journal of the American College of Cardiology. 2000 Jul;     [PubMed]
Hongo RH,Brent BN, Association of eptifibatide and acute profound thrombocytopenia. The American journal of cardiology. 2001 Aug 15;     [PubMed]
Tempelhof MW,Benzuly KH,Fintel D,Krichavsky MZ, Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. Texas Heart Institute journal. 2012;     [PubMed]
Oak MS,Rege NN, Eptifibatide: in the treatment of acute coronary syndromes. Journal of postgraduate medicine. 2000 Apr-Jun;     [PubMed]
O'Shea JC,Hafley GE,Greenberg S,Hasselblad V,Lorenz TJ,Kitt MM,Strony J,Tcheng JE, Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001 May 16;     [PubMed]
Sangkuhl K,Shuldiner AR,Klein TE,Altman RB, Platelet aggregation pathway. Pharmacogenetics and genomics. 2011 Aug;     [PubMed]
Dager WE,Dougherty JA,Nguyen PH,Militello MA,Smythe MA, Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;     [PubMed]
Gibson CM,Kirtane AJ,Murphy SA,Rohrbeck S,Menon V,Lins J,Kazziha S,Rokos I,Shammas NW,Palabrica TM,Fish P,McCabe CH,Braunwald E, Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. American heart journal. 2006 Oct     [PubMed]
Ohman EM,Kleiman NS,Gacioch G,Worley SJ,Navetta FI,Talley JD,Anderson HV,Ellis SG,Cohen MD,Spriggs D,Miller M,Kereiakes D,Yakubov S,Kitt MM,Sigmon KN,Califf RM,Krucoff MW,Topol EJ, Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation. 1997 Feb 18     [PubMed]
Adeoye O,Sucharew H,Khoury J,Vagal A,Schmit PA,Ewing I,Levine SR,Demel S,Eckerle B,Katz B,Kleindorfer D,Stettler B,Woo D,Khatri P,Broderick JP,Pancioli AM, Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial. Stroke. 2015 Sep     [PubMed]
Schrör K,Weber AA, Comparative pharmacology of GP IIb/IIIa antagonists. Journal of thrombosis and thrombolysis. 2003 Apr     [PubMed]
Coller BS, Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995 Nov 1     [PubMed]
Chong PH, Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1998 Nov 15     [PubMed]
Madan M,Berkowitz SD,Tcheng JE, Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998 Dec 8     [PubMed]
Leclerc JR, Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Critical care medicine. 2002 May     [PubMed]
Schneider DJ, Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. British journal of clinical pharmacology. 2011 Oct     [PubMed]


The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pharmacy-Technician (PTCB). The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pharmacy-Technician (PTCB), it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pharmacy-Technician (PTCB), you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pharmacy-Technician (PTCB). When it is time for the Pharmacy-Technician (PTCB) board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pharmacy-Technician (PTCB).